Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Liabilities and Shareholders Equity (2016 - 2025)

Enanta Pharmaceuticals' Liabilities and Shareholders Equity history spans 14 years, with the latest figure at $329.5 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 5.49% year-over-year to $329.5 million; the TTM value through Dec 2025 reached $1.2 billion, down 19.73%, while the annual FY2025 figure was $280.7 million, 25.47% down from the prior year.
  • Liabilities and Shareholders Equity reached $329.5 million in Q4 2025 per ENTA's latest filing, up from $280.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $495.2 million in Q2 2023 to a low of $280.7 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $389.8 million, with a median of $392.0 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: grew 28.54% in 2023, then decreased 25.47% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $440.6 million in 2021, then fell by 21.12% to $347.5 million in 2022, then grew by 23.3% to $428.5 million in 2023, then fell by 18.64% to $348.6 million in 2024, then dropped by 5.49% to $329.5 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Liabilities and Shareholders Equity are $329.5 million (Q4 2025), $280.7 million (Q3 2025), and $301.0 million (Q2 2025).